CD33 and acute myeloid leukemia: It was also attempted to assist the chemotherapy action with humanized CD33 antibodies such as Gentuzumab Ozogamicin (GO), obtaining significantly improved event-free survival of newly diagnosed AML pediatric patients or whose with favorable and intermediate cytogenetic-risk disease but poor results with those with adverse-risk [40, 41].